Lastly, further research, i.e., overexpressing ARHGEF2 in CRPC or enzalutamide-resistant models and using patient-derived organoids which harbor AR deletion, low AR activity or no AR expression models may be a more interesting way to demonstrate ARHGEF2 function in prostate cancer. This evidence concerns the gene ARHGEF2 and prostate carcinoma.